Otonomy and AGTC Present Preclinical Results for Gene Therapy Hearing Loss Program

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced preclinical results from the company’s gene therapy collaboration with UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, that support the selection of a product candidate for development as a treatment for gap junction beta-2 (GJB2) deficiency, the most common cause of congenital hearing loss.